Sunday, 22 November 2026 X LinkedIn Bluesky RSS Send us news
LungDaily The Pulse of Respiratory Health
New Paper Alert

Phase I trial of trispecific T-cell engager clesitamig reports 20.8% response rate in SCLC

Stephen V Liu summarised phase I data on clesitamig, noting cytokine release syndrome was manageable with step-up dosing but that anti-drug antibodies reduced drug exposure.

“immunogenicity an issue with all pts developing ADAs, which reduced exposure.”— Stephen V Liu, MD

A phase I study of clesitamig, a DLL3 x CD3 x 4-1BB trispecific T-cell engager, has been published in a journal tagged as @jitcancer, according to a post on X by thoracic oncologist Stephen V Liu.

Liu said cytokine release syndrome (CRS) occurred in 46.3% of patients. He wrote that with step-up dosing, all cases were grade 2 or lower.

In small cell lung cancer (SCLC), Liu reported a response rate of 20.8% and a duration of response of 4.4 months.

Liu also highlighted immunogenicity as an issue. He wrote that all patients developed anti-drug antibodies (ADAs), which reduced exposure to the drug.

The figures above come from Liu's summary of the study rather than from the full paper.

Original source

#lung-cancer#trial#therapeutics

Related stories

More in New Paper Alert

See all

LungDaily reports on public posts, papers and news from the lung health community. This article is based on the source linked above and was produced with AI-assisted tools under our editorial standards; facts and quotes are checked against the original before publication. Featured here, or spotted an error? Request a correction or removal.